Nurix Therapeutics Announces Closing of Underwritten Registered Offering

Strategic Insights -

Nurix Therapeutics, a clinical-stage biopharmaceutical company, has announced the successful completion of its underwritten registered offering of 24,485,799 shares of its common stock at a purchase price of $10.21 per share, generating gross proceeds of $250.0 million. The company plans to use the net proceeds from this offering primarily to fund the clinical development of its drug candidates, including bexobrutideg (NX-5948) in chronic lymphocytic leukemia (CLL) and the exploration of potential autoimmune indications. The offering included participation from both new and existing investors, including General Atlantic, Redmile Group, Braidwell LP, and others.

Key Takeaways:

  • Nurix Therapeutics has completed an underwritten registered offering of 24,485,799 shares of its common stock at a purchase price of $10.21 per share.
  • The gross proceeds from the offering were $250.0 million, which Nurix plans to use primarily to fund the clinical development of its drug candidates.
  • The company is focused on developing targeted protein degradation medicines, including bexobrutideg (NX-5948) in CLL and potential autoimmune indications.
  • Nurix's clinical stage pipeline includes degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B).
  • The company has partnerships with several major pharmaceutical companies, including Sanofi, Gilead, and Pfizer, to develop its drug candidates.
  • Nurix aims to establish degrader-based treatments at the forefront of patient care and is headquartered in San Francisco, California.

Statistics:

  • 24,485,799 shares of common stock were offered at a purchase price of $10.21 per share, generating gross proceeds of $250.0 million.
  • The offering included participation from both new and existing investors, including General Atlantic, Redmile Group, Braidwell LP, and others.
  • Nurix's clinical stage pipeline includes 7 degraders and degrader antibody conjugates (DACs) in various stages of development.
  • 5 of Nurix's drug candidates are in clinical trials, including bexobrutideg (NX-5948) in CLL and several programs in collaboration with Gilead, Sanofi, and Pfizer.

Sources:

  • GlobeNewswire, "Nurix Therapeutics Announces Closing of Underwritten Registered Offering" (October 27, 2025)
  • SEC, Form S-3 Registration Statement (File No. 333-280117)
  • SEC, Prospectus Supplement and Accompanying Prospectus (October 27, 2025)